The Effect of Femoral Nerve Block on Postoperative Opioid Use After Anterior Cruciate Ligament (ACL) Reconstruction
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study evaluates the effect of a femoral nerve block on opioid requirements following anterior cruciate ligament (ACL) reconstruction. This is a double blind, prospective randomized controlled trial.
Condition or disease
Procedure: Administration of a femoral nerve block (bupivacaine HCL)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
12 Years to 17 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Schedule for primary elective anterior cruciate ligament reconstruction
Tolerance to bupivacaine
Tolerance to non-steroidal anti-inflammatory drugs (NSAIDs)
Patients who received a femoral nerve block more than 1 hour prior to surgery
Complex associated injuries or pre-existing conditions that will delay time to ambulation
Children with tibial avulsion fractures
Allergic and/or sensitive to bupivacaine and/or NSAIDs
30% over ideal body weight
Acute ACL reconstruction (done less than 2 weeks after injury)
Pre-existing femoral nerve injury
Psychiatric patients on psychotropic agents
History of drug or alcohol dependence or recreational drug use